Somatostatin-dopamine chimeric analogs

1. A somatostatin-dopamine chimeric compound of the formula (I),

wherein:

X is H, Cl, Br, I, F, —CN, or C 1-5 alkyl;

R1 is H, C 1-4 alkyl, allyl, alkenyl or —CN;

R2 and R3, each are, independently H or absent, provided that R2 and R3 are not both absent;

R4 is H or —CH 3 ;

Y is —O—, —C(O)—, —S—, —S—(CH 2 )s-C(O)—, —S(O)—, —S(O) 2 —, —SC(O)—, —OC(O)—, —N(R5)-C(O)—, or —N(R6)-;

R5, R6, R7 and R8 each is, independently, H or C 1-5 aikyl;

m is 0 or 1;

n is 0-10;

L is —(CH 2 )p-C(O)—, when Y is —S—, —S(O)—, —S(O) 2 —, —O— or —N(R6)-;

L is —C(O)—(CR7R8)q-C(O)—, when Y is —N(R6)-, —O—, or —S—;

L is -(Doc)t-, when Y is —C(O)—, SC(O)—, —OC(O)—, —S—(CH 2 )s-C(O)—, or —N(R5)-C(O)—;

p is 1-10;

q is 2-4;

s is 1-10;

t is 1-10;

wherein said dopamine moiety binds to a dopamine D2 receptor; and

Z is an SSTR-2 peptide somatostatin analog selected from the group consisting of;

D-Nal-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH 2 ;

D-Phe-cyclo[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH 2 ;

D-Phe-cyclo[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH 2 ;

D-Phe-cyclo[Cys-(3-Bromo-Tyr)-D-Trp-Lys-Thr-Cys]-Thr-NH 2 ;

D-Ser-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-NH 2 ;

D-Ser-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol;

D-Tyr-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-NH 2 ;

D-Tyr-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol;

D-Phe-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol;

D-Phe-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH 2 ;

D-Ser-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH 2 ;

D-Tyr-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH 2 ;

D-Phe-cyclo[D-Cys-Pal-D-Trp-Lys-D-Cys]-Thr-(Bzl)-Tyr-NH 2 ;

cyclo[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH 2 ;

D-Tyr-cyclo[Cys-Phe-Phe-D-Trp-Lys-Thx-Phe-Cys]-NH 2 ;

cyclo[Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys]-NH 2 ;

D-Tyr-cyclo[Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys]-NH 2 ;

Ser-cyclo[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH 2 ;

D-Phe-cyclo[Cys-Phe-D-Trp-Lys-Val-Cys]-Thr-NH 2 ;

D-Tyr-cyclo[Cys-Phe-D-Trp-Lys-Val-Cys]-Thr-NH 2 ;

D-Tyr-cyclo[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH 2 ;

D-Phe-cyclo[Cys-(3-Iodo-Tyr)-D-Trp-Lys-Val-Cys]-Thr-NH 2 ;

or a pharmaceutically acceptable salt thereof.

2. A somatostatin-dopamine chimeric compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein said dopamine moiety binds to a dopamine D2 receptor.

3. A somatostatin-dopamine chimeric compound according to the formula:

or a pharmaceutically acceptable salt thereof.

4. A somatostatin-dopamine chimeric compound according to the formula:

6-Methyl-8β-ergolinylmethylthioacetyl-D-Phe-c(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH 2 ;

6-n-propyl-8β-ergolinylmethylthioacetyl-D-Phe-c(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH 2 ;

6-D-Methyl-8β-ergolinylmethylthlaminosuccinoyl-D-Phe-c(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thi-NH 2 ;

or a pharmaceutically acceptable salt thereof.

5. A somatostatin-dopamine chimeric compound according to the formula:

or a pharmaceutically acceptable salt thereof.

6. A composition comprising a compound according to any one of claims 1 or 2 - 5 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition according to claim 6 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.